Abstract
Inflammatory bowel diseases are chronic diseases that affect the gastrointestinal tract. Mesalamine, corticosteroids, immunosuppressants and biological agents are currently used to treat these diseases. Due to inadequacies of the currently available delivery systems, a large number of patients do not respond to treatment, especially when they are affected by distal colonic disease. Multimatrix (MMX™) technology comprises hydrophilic and lipophilic excipients, enclosed within a gastro-resistant, pH-dependent coating. This new delivery technology has been used to modify some commonly used drugs, including mesalamine and budesonide, as well as heparin, which are now being investigated for their utility in the management of IBD. Aim: The aim of this review is to explore the MMX delivery technology and its efficacy for the treatment of IBD. Results: The results of various studies involving MMX drugs have been published. Mesalamine MMX induces clinical and endoscopic remission in patients with mild to moderate ulcerative colitis (UC) compared with placebo. Positive results have also been observed with MMX budesonide in two phase I studies. In a pilot study involving ten patients with UC, efficacy of heparin-MMX as an IBD therapy was observed. Conclusion: MMX is a promising new delivery system that can improve efficacy of current and new drugs, augmenting targeting to the affected tract, thereby increasing response and remission rates for those drugs in patients with IBD.
Keywords: Multimatrix, MMX, Crohn, Colitis, IBD, mesalamine, budesonide, heparin
Current Medicinal Chemistry
Title: New Drug Delivery Systems in Inflammatory Bowel Disease: MMX™ and Tailored Delivery to the Gut
Volume: 17 Issue: 17
Author(s): G. Fiorino, W. Fries, S.A. De La Rue, A.C. Malesci, A. Repici and S. Danese
Affiliation:
Keywords: Multimatrix, MMX, Crohn, Colitis, IBD, mesalamine, budesonide, heparin
Abstract: Inflammatory bowel diseases are chronic diseases that affect the gastrointestinal tract. Mesalamine, corticosteroids, immunosuppressants and biological agents are currently used to treat these diseases. Due to inadequacies of the currently available delivery systems, a large number of patients do not respond to treatment, especially when they are affected by distal colonic disease. Multimatrix (MMX™) technology comprises hydrophilic and lipophilic excipients, enclosed within a gastro-resistant, pH-dependent coating. This new delivery technology has been used to modify some commonly used drugs, including mesalamine and budesonide, as well as heparin, which are now being investigated for their utility in the management of IBD. Aim: The aim of this review is to explore the MMX delivery technology and its efficacy for the treatment of IBD. Results: The results of various studies involving MMX drugs have been published. Mesalamine MMX induces clinical and endoscopic remission in patients with mild to moderate ulcerative colitis (UC) compared with placebo. Positive results have also been observed with MMX budesonide in two phase I studies. In a pilot study involving ten patients with UC, efficacy of heparin-MMX as an IBD therapy was observed. Conclusion: MMX is a promising new delivery system that can improve efficacy of current and new drugs, augmenting targeting to the affected tract, thereby increasing response and remission rates for those drugs in patients with IBD.
Export Options
About this article
Cite this article as:
Fiorino G., Fries W., De La Rue S.A., Malesci A.C., Repici A. and Danese S., New Drug Delivery Systems in Inflammatory Bowel Disease: MMX™ and Tailored Delivery to the Gut, Current Medicinal Chemistry 2010; 17 (17) . https://dx.doi.org/10.2174/092986710791111170
DOI https://dx.doi.org/10.2174/092986710791111170 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dual Acting Anti-Inflammatory Drugs
Current Topics in Medicinal Chemistry Extensive Phytochemistry, Comprehensive Traditional Uses, and Critical Pharmacological Profile of the Great Mullein: Verbascum thapsus L
The Natural Products Journal Can Genetics Help in Treatment of Smoking Addiction?
Current Pharmacogenomics and Personalized Medicine Kinases as Drug Targets in Inflammation: In Vitro and In Vivo Target Validation and Expression Profiling
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Transient Receptor Potential Vanilloid 1 Channel Modulation: A Novel Approach to Pain Therapy
Current Bioactive Compounds The Pathogenic Role of Persistent Milk Signaling in mTORC1- and Milk- MicroRNA-Driven Type 2 Diabetes Mellitus
Current Diabetes Reviews Anti-Hyperglycemic and Hypolipidemic Effects of Different Aloe vera (Aloe Barbadensis Miller) Extracts in the Management of Obesity and Diabetes
Current Nutrition & Food Science Screening and Partial Purification of Cholinesterase Inhibitor from Microalgae
Current Enzyme Inhibition The Interplay Between Inflammation and Oxidative Stress in Carcinogenesis
Current Molecular Medicine Mucosal Immunisation: Adjuvants and Delivery Systems
Current Drug Delivery Preface: MicroRNA as Disease Biomarkers
MicroRNA Chemokines and Their Receptors: Potential Therapeutic Targets for Bone Cancer Pain
Current Pharmaceutical Design Milk Fermented with a 15-Lipoxygenase-1-Producing Lactococcus Lactis Alleviates Symptoms of colitis in a Murine Model
Current Pharmaceutical Biotechnology Single Nucleotide Polymorphisms in Neonatal Necrotizing Enterocolitis
Current Pediatric Reviews Impact of IL-17 on Cells of the Monocyte Lineage in Health and Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Endometriosis and Gynecological Cancer
Current Women`s Health Reviews Oral Nano-Delivery Systems for Colon Targeting Therapy
Pharmaceutical Nanotechnology Momordica balsamina: A Medicinal and Neutraceutical Plant for Health Care Management
Current Pharmaceutical Biotechnology Skeletal Effects of Drugs to Treat Cancer
Current Drug Safety Adhesion Molecules as Targets for the Treatment of Neoplastic Diseases
Current Pharmaceutical Design